Work

Case report: Toxic epidermal necrolysis induced by tislelizumab in a patient with esophageal squamous cell carcinoma

Year: 2024

Type: article

Abstract: Background: Immune checkpoint inhibitors (ICIs) have been widely applicated for the treatment of patients with advanced esophageal cancer. Skin-related adverse reactions are frequent with ICIs, with toxic epidermal necrolysis (TEN) being a severe and potentially life-threatening cutaneous reaction. Case presentation: We present a case of a 70-year-old male with locally advanced esophageal cancer who developed severe toxic epidermal necrolysis (TEN) after 18 days of tislelizumab combined with chemotherapy. The condition rapidly progressed to cover approximately 90% of his body. After treatment with intravenous methylprednisolone, immunoglobulin, and antibiotics, along with active nutritional support and wound care, the patient recovered from TEN induced by tislelizumab. Conclusion: Treatment for TEN is complex, and no standardized guidelines currently exist. We propose an economical, safe, effective, and simple strategy for similar TEN patients.

Source: Frontiers in Medicine

DOI: 10.3389/fmed.2024.1522525

Authors: Shilong Wu, Chenyang Xu, Huafeng Liu

Institution: Ganzhou People's Hospital

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,295